Oncolytic Immunotherapy

DALLAS, May 15, 2026 CG Oncology announced positive initial Phase 2 data from the CORE-008 Cohort CX trial, evaluating...

WESTLAKE VILLAGE, Calif. | January 5, 2026 — Genelux Corporation, a late clinical-stage immuno-oncology company, has reported encouraging interim...